Presentation of Interim Report Q2

CEO comments – Q2 2026

- **Strong financial and operational results**
  - Revenue growth of 25% in local currencies
  - Adjusted EBIT at 15%, in line with financial target
- **Educational Products 24% growth in local currencies**
  - EMEA +60%, and building momentum in the US market
  - Ultrasound segment 34% growth, with structural tailwind
  - New products in for obstetrics training and within endovascular simulation for our Angio Mentor platform
- **Industry 27% growth in local currencies**
  - License revenue growth of 44%, from several customers
  - Very dynamic robotics surgery market, with strong interest for our products and services

Revenue
SEK 254.5m
+22% reported | +25% fx-adj

Adjusted EBIT
SEK 38.2m
15% margin | 14% fx-adj

License revenue
SEK 84.8m
33% of sales | +44% vs Q2'25

Gross margin
69%
+4pp vs Q2 2025 (65%)

Operating cash flow
SEK 15.3m
vs SEK 16.2m Q2 2025

Cash & equivalents
SEK 658.4m
No debt financing



*This year's event, **Society for Robotic Surgery** (Orlando, FL), generated strong interest in our product and services,*
and a record number of attendees and exhibitors.

surgicalscience

CEO comments – Q2 2026

- **Strong financial and operational results**
  - Revenue growth of 25% in local currencies
  - Adjusted EBIT at 15%, in line with financial target
- **Educational Products 24% growth in local currencies**
  - EMEA +60%, and building momentum in the US market
  - Ultrasound segment 34% growth, with structural tailwind
  - New products in for obstetrics training and within endovascular simulation for our Angio Mentor platform
- **Industry 27% growth in local currencies**
  - License revenue growth of 44%, from several customers
  - Very dynamic robotics surgery market, with strong interest for our products and services
  - Weaker revenues for Medical Device Simulation, but with solid underlying customer demand and increasing pipeline
- **Gross margin (GM) improvement driven by positive GM development in our simulator business, and increasing share of license revenues**
- **New production facility in Tel Aviv, and Service Hub in Hong Kong opened**
- **Full focus on strategy execution to grow our five market segments, and to improve our financial performance further**

Revenue

SEK 254.5m

+22% reported | +25% fx-adj

Adjusted EBIT

SEK 38.2m

15% margin | 14% fx-adj

License revenue

SEK 84.8m

33% of sales | +44% vs Q2'25

Gross margin

69%

+4pp vs Q2 2025 (65%)

Operating cash flow

SEK 15.3m

vs SEK 16.2m Q2 2025

Cash & equivalents

SEK 658.4m

No debt financing

Q2: Strong license revenues and improved profitability



	Q2 2024	Q3	Q4	Q1 2025	Q2	Q3	Q4	Q1 2026	Q2
Industry	102,4	103,6	126,5	127,7	99,1	124,7	139,3	105,5	123,0
Educational Products	110,1	128,3	125,0	122,9	110,1	139,0	129,5	130,0	131,5

Q2:

- Net sales up 22% to SEKm 254.5 (209.2). In local currencies up 25%.
- Educational Products up 19%, 24% excl. FX. Regions: EMEA +60%, APAC +10%, Americas +4%.
- Industry up 24%, 27% excl. FX. License revenues up 44%, SEKm 84.8 (58.9). Simulator sales SEKm 18.6 (15.0). Development revenues SEKm 14.7 (22.3).

H1:

- Net sales up 7% to SEKm 490.0 (459.8). In local currencies up 11%.
- Educational Products up 12%, 15% excl. FX.
- Industry up 1%, 7% excl. FX.

surgicalscience

Revenue streams



	Q2 2024	Q3	Q4	Q1 2025	Q2	Q3	Q4	Q1 2026	Q2
Development revenue	8,2	9,5	4,7	10,5	22,3	21,9	21,5	14,3	14,7
License revenue	67,1	65,0	76,4	83,8	58,9	65,5	92,3	67,6	84,8
Service revenue	22,2	22,2	20,9	21,9	22,8	22,6	23,8	22,5	23,9
Simulators	114,9	135,2	149,6	134,4	105,2	153,6	131,2	131,1	131,2

Q2:

- License revenues: 33% (28) of total revenues. Intuitive revenues for H1 in line with H1 2025 in USD. Assessment that total revenue loss due to cancelled MoU will be less than the interval previously stated (SEKm 60-90).
- Simulator sales up 25%.
- Development revenues weaker than previous year.
- Stable service revenues.

H1:

- License revenues: 31% (31) of total revenues, up 7%, SEKm 152.4 (142.7).

surgicalscience

Costs and EBIT margin

Costs/margin as a percentage of sales

Q2:

- Gross margin 69% (65). Higher license revenue, increased direct sales within Edu and price increases had a positive effect.
- Sales: 19% (28) of sales. SEKm 1.2 in tariff refunds relating to the corresponding quarter in 2025.
- Admin: 9% (11) of sales. SEKm 1.1 related to uplift listing process. Work with new legal entities in Hong Kong and China.
- R&D: 23% (25) of sales. Activated costs SEKm 13.7 (10.1).
- Other: Option programs, FX-effects.
- EBIT SEKm 32.7 (-22.4), 13% (-11). FX-adjusted EBIT SEKm 31.2 or 12%.

H1:

- Gross margin 68% (67). Negative effect from currencies 1 pp.
- EBIT SEKm 55.6 (1.5), 11% (0). FX-adjusted EBIT SEKm 67.6 or 13%.

surgicalscience

Organization

Offices / Development sites

No of employees at end of period: 319 (327)





* Other: Primarily Germany and China.

surgicalscience

Adjusted EBIT*



Q2:

- Adjusted EBIT SEKm 38.2 (-16.7), 15% (-8).
- FX-adjusted adjusted EBIT SEKm 34.3, 14%.

H1:

- Adjusted EBIT SEKm 66.5 (13.4), 14% (3).
- FX-adjusted adjusted EBIT SEKm 76.8, 15%.

*Excluding acquisition and restructuring costs related to IU in Q1 and Q3 2025 and Seattle in Q4 2025.

surgicalscience

Finance net and taxes

Q2:

- Finance net SEKm -0.9 (3.7). Interest on bank balances, revaluation of internal loans and IFRS 16 effect.
- Tax expense SEKm 10.9 (1.4).
- Net result SEKm 20.8 (-20.1).

H1:

- Finance net SEKm -2.1 (25.9).
- Tax expense SEKm 13.9 (14.3).
- Net result SEKm 39.5 (13.2).

surgicalscience

Cash flow



Q2:

- Cash flow from operating activities SEKm 15.3 (16.2). Change in working capital SEKm -20.8 (20.0). Inventory, A/R and current receivables increased.
- Cash flow from investing activities SEKm -21.8 (-12.6) mainly investments in development costs. SEKm 6.1 invested in production facility in Tel Aviv.
- Cash flow from financing activities SEKm -2.7 (-3.5).
- Cash at end of period SEKm 658.4 (610.2).
- A/R as % of sales LTM at good level.

H1:

- Cash flow from operating activities SEKm 80.6 (11.3). Change in working capital SEKm 14.8 (-14.1). Inventory increased, A/R decreased.

surgicalscience

Thank you

Find out more at:
www.surgicalscience.com